Andrea Natale is a Cardiology physician. ClinicalTrials.gov lists 28 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3000 N. Ih-35, Suite 700
Austin, TX 787051804
Telephone
512-807-3150Registry record last updated 21 Jul 2022.
Clinical trials
- Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
Sponsor: Boston Scientific Corporation
- AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Sponsor: Peerbridge Health, Inc
- Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers (SAFFICIENT)
Sponsor: Texas Cardiac Arrhythmia Research Foundation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202598 payments$152,625openpaymentsdata.cms.gov ↗
- Biosense Webster, Inc.Program year202590 payments$146,897openpaymentsdata.cms.gov ↗
- Pulse Biosciences, Inc.Program year202524 payments$36,000openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
38.4%Factor Xa inhibitor37.5%Eliquis74%Xarelto26%Part D≥88 patientsLow Molecular Weight Heparin1%Enoxaparin Sodium100%Part D<11 patientsCardiovascular
36.6%Beta blocker12%Metoprolol Succinate43%Metoprolol Tartrate31%Sotalol26%Part D≥23 patientsAntiarrhythmic11.5%Flecainide Acetate52%Multaq37%Propafenone Hcl11%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
11.3%Potassium supplement11.3%Potassium Chloride83%Klor-Con M2017%Part D≥98 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”